Cargando…
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
Activation of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is a key oncogenic mechanism in a growing number of tumor types. In the majority of cases, ALK is activated by fusion with a dimerizing partner protein as a result of chromosomal translocation events, most studied in the cas...
Autores principales: | Sattu, Kamaraj, Hochgräfe, Falko, Wu, Jianmin, Umapathy, Ganesh, Schönherr, Christina, Ruuth, Kristina, Chand, Damini, Witek, Barbara, Fuchs, James, Li, Pui-Kai, Hugosson, Fredrik, Daly, Roger J, Palmer, Ruth H, Hallberg, Bengt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892176/ https://www.ncbi.nlm.nih.gov/pubmed/23889739 http://dx.doi.org/10.1111/febs.12453 |
Ejemplares similares
-
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019) -
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016) -
Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
por: Guan, Jikui, et al.
Publicado: (2017) -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018) -
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)